Alnylam Pharmaceuticals (ALNY) Consolidated Net Income (2009 - 2026)

Alnylam Pharmaceuticals' Consolidated Net Income history runs 18 years deep, the most recent figure standing at $206.0 million for Q1 2026.

• Quarterly Consolidated Net Income rose 1228.66% year-over-year to $206.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $543.9 million (up 336.01% YoY) and the FY2025 annual result came in at $313.8 million, up 212.8% from the prior year.
• Consolidated Net Income was $206.0 million for Q1 2026 at Alnylam Pharmaceuticals, up from $111.5 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $292.7 million in Q3 2025 and bottomed at -$405.9 million in Q3 2022.
• A 5-year average of -$77.9 million and a median of -$83.8 million in 2024 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2025 — Consolidated Net Income slumped 292.43% — and 2026, when it soared 1228.66%.
• Alnylam Pharmaceuticals' Consolidated Net Income stood at -$207.5 million in 2022, then surged by 33.55% to -$137.9 million in 2023, then surged by 39.24% to -$83.8 million in 2024, then surged by 233.17% to $111.5 million in 2025, then soared by 84.67% to $206.0 million in 2026.
• Business Quant data shows ALNY's Consolidated Net Income at $206.0 million in Q1 2026, $111.5 million in Q4 2025, and $292.7 million in Q3 2025.